Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06307054
Status:
RECRUITING
Last Update Posted:
2024-03-12
First Post:
2024-02-28
Brief Title:
CLL-1 CAR-NK Cells for RelapsedRefractory AML
Sponsor:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Organization:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With RelapsedRefractory Acute Myeloid Leukemia
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-arm open-label dose-escalation clinical trial aimed at exploring the safety tolerability and pharmacokinetic characteristics of the CLL-1 CAR NK cells as well as providing preliminary observations on its efficacy in subjects with relapsedrefractory acute myeloid leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None